Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 20, 2006. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction within a retirement plan rather than general financial performance.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK Ordinary Share ADRs), the Administrators notified the company of an increase in the notional allocation of Ordinary Share ADRs on June 16, 2006. The transaction occurred at a price of $53.84 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a compliance notification under Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: June 16, 2006
- Notification Date: June 20, 2006
- Share Price: $53.84 per share
- Involved Parties: Dr. R Greig (7 shares) and Dr. M Slaoui (6 shares)
- Plan Type: US Retirement Savings Plan (notional investment in GSK Ordinary Share ADRs)